Global Pulmonary Drugs Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are rising enormously across the globe. Pulmonary drugs are the drugs used to treat chronic obstructive pulmonary disease. It helps to reduce shortness of breath, prevent exacerbations, and control coughing and wheezing. Some of the pulmonary drugs are used with devices called nebulizers or inhalers.
The factors that are playing a major role in the growth of Pulmonary Drugs Market are rising number of patients with chronic respiratory diseases and growing number of smokers around the world. In addition, increasing investments for research and development to produce effective drugs is another factor driving overall market. On the other hand, the strict regulatory process for drug approval and availability of counterfeit drugs will slow down and hinder the growth of the overall market.
Pulmonary Drugs Market is segmented based on drug class, distribution channel, application, and region. Drug class such as Combination Drugs, Inhaled Corticosteroids (ICS), Anticholinergics, Long-Acting Beta2-Agonists (LABA), Short-Acting Beta2-Agonists (SABA), Antihistamines, Vasodilators, and others (Antieukotrienes, MAbs, Antileukotrienes, Antibiotics, and others) classify the market.
Distribution Channel such as E-Commerce, Hospital Pharmacies, Drug Stores, Retail Pharmacies, and others classify Pulmonary Drugs Market. Application into Cystic Fibrosis, Asthma & COPD, Pulmonary Arterial Hypertension, Allergic Rhinitis, and others classify Pulmonary Drugs Market. Pulmonary Drugs Market is segmented geographically Americas (North America, Latin America), Europe (Eastern Europe, Western Europe), Asia Pacific, Latin America, Middle East and Africa. Globally, North America accounts for the largest market share of the industry and is estimated to lead the overall market in the upcoming years. Europe and Asia Pacific follow suit. On the other hand, Asia Pacific is estimated to grow at fastest pace in the upcoming years. The reason being, high medical demands.
The key players of Pulmonary Drugs Market are Sunovion Pharmaceuticals Inc., AstraZeneca plc., GlaxoSmithKline plc, Bayer AG, Novartis AG, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Actelion Pharmaceuticals, Inc. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As such, mergers, acquisitions, and joint ventures are the need of the hour.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Pulmonary Drugs in these regions, from 2013 to 2025 (forecast), covering
• North America
• Southeast Asia
Global Pulmonary Drugs market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• AstraZeneca plc
• Bayer AG
• Teva Pharmaceutical Industries Ltd
• Actelion Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• F. Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• GlaxoSmithKline plc
• Sunovion Pharmaceuticals
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
• Inhaled Corticosteroids (ICS)
• Long-Acting Beta2-Agonists (LABA)
• Short-Acting Beta2-Agonists (SABA)
• Combination Drugs
• Antibiotics & Antileukotrienes
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
• Asthma & COPD
• Allergic Rhinitis
• Pulmonary Arterial Hypertension
• Cystic Fibrosis
Research Support Specialist, USA